Open access
A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)
Jun-Sung Moon
K. Han
Dong-Lim Kim
Sang Yong Kim
Soo-Kyung Kim
B. J. Ku
Woo-Je Lee
Tae Keun Oh
Ji A. Seo
Sang-Ah Chang
Moon-Kyu Lee
Kyu-Jeung Ahn
Chul Sik Kim
Tae Nyun Kim
Bong-Soo Cha
Oct 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11955 - 11965 · 0 citations
· 18 references
Medicine
Abstract
To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin.